Consequently, patients with AR-V7-expressing prostate cancer (Figure 3) exhibit resistance to the antiandrogen drugs enzalutamide (AR antagonist) and abiraterone (inhibitor of steroidogenic enzyme CYP17A1) [121]. Here, AR is linked to prostate cancer.